6CM
IMRX icon

683 Capital Management’s Immuneering IMRX Stock Holding History

683 Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-150,697
Closed -$794K – 193
2026
Q1 		$794K Hold
150,697
– – 0.04% 149
2025
Q4 		$992K Buy
+150,697
New +$968K 0.04% 142

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

683 Capital Management's IMRX Position: Q2 2026 in Review

683 Capital Management sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 150,697 shares — an estimated $794K sold.

683 Capital Management first reported a position in IMRX in Q4 2025 and held it in 2 quarters. The position peaked at $992K in Q4 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • 683 Capital Management reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 150,697 Immuneering shares in Q2 2026, an estimated $794K.
  • 683 Capital Management first reported a position in Immuneering in Q4 2025 and held it in 2 quarters.
  • 683 Capital Management's Immuneering position peaked at $992K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.